Creo Medical Limited
CREO.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.4B
Close$
$-10.20
197.2% downside
Current Fair Value
197.2% downsideOvervalued by 197.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.40 Billion |
|---|---|
| Enterprise Value | $4.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.01 |
| Beta | 1.56 |
| Outstanding Shares | 418,584,430 |
Return
| Return on Equity | -29.46% |
|---|---|
| Return on Assets | -25.00% |
| Return on Invested Capital | -86.33% |
Valuation & Multiples
| P/E Ratio | -2.32 |
|---|---|
| PEG | 1.63 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 179.99 |
| Enterprise Value to EBIT | -103.82 |
| Enterprise Value to Net Income | -310 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$3.20 M
Average shareholder expectationNext Earnings Call
Expected Date
June 2, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$5.80 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Creo Medical Limited
104 employees
CEO: Craig Jonathan Gulliford Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd...